Sonnet BioTherapeutics Holdings, Inc. Logo

Sonnet BioTherapeutics Holdings, Inc.

SONN

(0.8)
Stock Price

2,10 USD

-137.76% ROA

-398.33% ROE

-3.08x PER

Market Cap.

3.173.527,00 USD

5.74% DER

0% Yield

-14289.97% NPM

Sonnet BioTherapeutics Holdings, Inc. Stock Analysis

Sonnet BioTherapeutics Holdings, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Sonnet BioTherapeutics Holdings, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (6%), which means it has a small amount of debt compared to the ownership it holds

2 Graham Number

The Graham number analysis indicates that this company's stock price is likely undervalued, raising prospects for a favorable investment opportunity.

3 ROE

The stock's ROE indicates a negative return (-3332%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-225.06%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's elevated P/BV ratio (12.37x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Sonnet BioTherapeutics Holdings, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Sonnet BioTherapeutics Holdings, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Sell
4 Stoch RSI Sell

Sonnet BioTherapeutics Holdings, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Sonnet BioTherapeutics Holdings, Inc. Revenue
Year Revenue Growth
2013 17.496.810
2014 0 0%
2015 42.396.809 100%
2016 41.702.001 -1.67%
2017 41.432.863 -0.65%
2018 30.733.472 -34.81%
2019 40.613.709 24.33%
2020 0 0%
2021 483.626 100%
2022 349.943 -38.2%
2023 147.805 -136.76%
2024 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Sonnet BioTherapeutics Holdings, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2013 0
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 154.717 100%
2019 2.199.297 92.97%
2020 9.877.555 77.73%
2021 16.634.553 40.62%
2022 21.444.019 22.43%
2023 11.814.690 -81.5%
2024 6.823.976 -73.13%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Sonnet BioTherapeutics Holdings, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2013 0
2014 0 0%
2015 7.415.381 100%
2016 5.801.033 -27.83%
2017 4.545.496 -27.62%
2018 363.877 -1149.18%
2019 2.509.041 85.5%
2020 7.533.722 66.7%
2021 8.936.509 15.7%
2022 8.575.283 -4.21%
2023 7.125.732 -20.34%
2024 7.206.528 1.12%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Sonnet BioTherapeutics Holdings, Inc. EBITDA
Year EBITDA Growth
2013 -5.795.871
2014 0 0%
2015 -13.429.578 100%
2016 -278.190 -4727.48%
2017 -237.680 -17.04%
2018 -1.254.210 81.05%
2019 -4.708.338 73.36%
2020 -10.536.762 55.32%
2021 -24.970.233 57.8%
2022 -29.616.877 15.69%
2023 -18.676.790 -58.58%
2024 -14.030.480 -33.12%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Sonnet BioTherapeutics Holdings, Inc. Gross Profit
Year Gross Profit Growth
2013 17.496.810
2014 0 0%
2015 28.360.644 100%
2016 3.326.275 -752.62%
2017 2.025.017 -64.26%
2018 791.106 -155.97%
2019 32.680.388 97.58%
2020 -58.313 56143.06%
2021 -16.150.927 99.64%
2022 256.686 6392.1%
2023 72.055 -256.24%
2024 -84.156 185.62%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Sonnet BioTherapeutics Holdings, Inc. Net Profit
Year Net Profit Growth
2013 -5.961.228
2014 0 0%
2015 -12.136.526 100%
2016 -9.076.572 -33.71%
2017 -6.794.771 -33.58%
2018 -6.854.420 0.87%
2019 -5.034.084 -36.16%
2020 -31.060.640 83.79%
2021 -25.005.987 -24.21%
2022 -29.774.323 16.01%
2023 -18.832.694 -58.1%
2024 -14.022.220 -34.31%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Sonnet BioTherapeutics Holdings, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2013 -68.277
2014 0 0%
2015 -42.598 100%
2016 -33.503 -27.14%
2017 -21.549 -55.47%
2018 -15.593 -38.2%
2019 -5.776 -169.96%
2020 -1.016 -469.06%
2021 -314 -224.28%
2022 -151 -108.67%
2023 -18 -733.33%
2024 -3 -800%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Sonnet BioTherapeutics Holdings, Inc. Free Cashflow
Year Free Cashflow Growth
2015 -7.161.545
2016 -1.700.332 -321.19%
2017 -2.349.892 27.64%
2018 -2.808.381 16.33%
2019 -4.618.569 39.19%
2020 -15.690.962 70.57%
2021 -22.555.868 30.44%
2022 -28.583.755 21.09%
2023 -21.785.092 -31.21%
2024 -3.081.608 -606.94%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Sonnet BioTherapeutics Holdings, Inc. Operating Cashflow
Year Operating Cashflow Growth
2015 -5.363.324
2016 -509.158 -953.37%
2017 -724.432 29.72%
2018 -1.109.634 34.71%
2019 -2.225.705 50.14%
2020 -15.614.779 85.75%
2021 -22.552.245 30.76%
2022 -27.687.278 18.55%
2023 -21.341.842 -29.73%
2024 -3.069.608 -595.26%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Sonnet BioTherapeutics Holdings, Inc. Capital Expenditure
Year Capital Expenditure Growth
2015 1.798.221
2016 1.191.174 -50.96%
2017 1.625.460 26.72%
2018 1.698.747 4.31%
2019 2.392.864 29.01%
2020 76.183 -3040.94%
2021 3.623 -2002.76%
2022 896.477 99.6%
2023 443.250 -102.25%
2024 12.000 -3593.75%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Sonnet BioTherapeutics Holdings, Inc. Equity
Year Equity Growth
2007 3.475.276
2008 1.539.136 -125.79%
2009 718.018 -114.36%
2010 106.600.000 99.33%
2011 3.333.282 -3098.05%
2012 5.598.751 40.46%
2013 11.633.639 51.87%
2014 0 0%
2015 22.146.943 100%
2016 13.613.018 -62.69%
2017 11.488.884 -18.49%
2018 8.257.525 -39.13%
2019 -2.018.450 509.1%
2020 3.019.917 166.84%
2021 22.259.847 86.43%
2022 -2.538.719 976.81%
2023 -225.980 -1023.43%
2024 2.618.106 108.63%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Sonnet BioTherapeutics Holdings, Inc. Assets
Year Assets Growth
2007 3.824.543
2008 2.225.261 -71.87%
2009 1.453.669 -53.08%
2010 1.414.559.000 99.9%
2011 5.504.678 -25597.4%
2012 7.646.431 28.01%
2013 20.087.606 61.93%
2014 0 0%
2015 42.205.206 100%
2016 33.486.123 -26.04%
2017 30.183.019 -10.94%
2018 29.793.240 -1.31%
2019 39.754 -74844.01%
2020 7.994.408 99.5%
2021 28.993.810 72.43%
2022 5.830.012 -397.32%
2023 5.429.478 -7.38%
2024 5.796.797 6.34%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Sonnet BioTherapeutics Holdings, Inc. Liabilities
Year Liabilities Growth
2007 349.267
2008 686.125 49.1%
2009 735.651 6.73%
2010 1.332.134.000 99.94%
2011 3.863.415 -34380.74%
2012 2.117.878 -82.42%
2013 8.848.612 76.07%
2014 0 0%
2015 20.448.073 100%
2016 19.524.105 -4.73%
2017 18.694.135 -4.44%
2018 21.535.715 13.19%
2019 2.885.241 -646.41%
2020 4.974.491 42%
2021 6.733.963 26.13%
2022 8.368.731 19.53%
2023 5.655.458 -47.98%
2024 3.178.691 -77.92%

Sonnet BioTherapeutics Holdings, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-1.59
Price to Earning Ratio
-3.08x
Price To Sales Ratio
56.79x
POCF Ratio
-2.46
PFCF Ratio
-0.31
Price to Book Ratio
9.39
EV to Sales
-4.13
EV Over EBITDA
0.02
EV to Operating CashFlow
0.02
EV to FreeCashFlow
0.02
Earnings Yield
-0.32
FreeCashFlow Yield
-3.21
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
4.31
Graham NetNet
0.15

Income Statement Metrics

Net Income per Share
-1.59
Income Quality
1.25
ROE
-3.98
Return On Assets
-1.38
Return On Capital Employed
-4.57
Net Income per EBT
1
EBT Per Ebit
0.65
Ebit per Revenue
-219.69
Effective Tax Rate
-0.01

Margins

Sales, General, & Administrative to Revenue
106.5
Research & Developement to Revenue
113.09
Stock Based Compensation to Revenue
3.95
Gross Profit Margin
-0.45
Operating Profit Margin
-219.69
Pretax Profit Margin
-142.9
Net Profit Margin
-142.9

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-1.98
Free CashFlow per Share
-2.02
Capex to Operating CashFlow
-0.02
Capex to Revenue
3.26
Capex to Depreciation
2.25
Return on Invested Capital
-4.48
Return on Tangible Assets
-1.38
Days Sales Outstanding
3393.96
Days Payables Outstanding
8469.77
Days of Inventory on Hand
0
Receivables Turnover
0.11
Payables Turnover
0.04
Inventory Turnover
0
Capex per Share
0.04

Balance Sheet

Cash per Share
0,71
Book Value per Share
0,52
Tangible Book Value per Share
0.52
Shareholders Equity per Share
0.52
Interest Debt per Share
0.04
Debt to Equity
0.06
Debt to Assets
0.03
Net Debt to EBITDA
0.28
Current Ratio
1.65
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
2183463
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Sonnet BioTherapeutics Holdings, Inc. Dividends
Year Dividends Growth

Sonnet BioTherapeutics Holdings, Inc. Profile

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

CEO
Dr. Pankaj Mohan Ph.D.
Employee
12
Address
100 Overlook Center
Princeton, 08540

Sonnet BioTherapeutics Holdings, Inc. Executives & BODs

Sonnet BioTherapeutics Holdings, Inc. Executives & BODs
# Name Age
1 Mr. Jay Cross
Chief Financial Officer
70
2 Mr. Donald J. Griffith CPA, CPA
Controller & Director
70
3 Ms. Susan Dexter
Chief Technical Officer
70
4 Dr. John K. Cini Ph.D.
Chief Scientific Officer & Co-Founder
70
5 Dr. Pankaj Mohan Ph.D.
Founder, Chairman, Chief Executive Officer & President
70
6 Dr. Richard T. Kenney FACP, M.D.
Chief Medical Officer
70
7 Mr. Manuel Dafonseca
Head of Clinical Operations
70

Sonnet BioTherapeutics Holdings, Inc. Competitors